Facebook Instagram Twitter RSS Feed Back to top on side

Information Page of SAS Organisation

Project

Centre of Experimental Medicine SAS

International Projects

Anti-inflammatory effect of astaxanthin, sulforaphane and Crocus sativus extract evaluated in two rodent models of age related diseases.

-

Duration: 1. 1. 2018 - 31. 12. 2021
Program: Medziakademická dohoda (MAD)
Project leader: PharmDr. Bauerová Katarína PhD., DrSc.

EU-NETVAL International Thyroid Validation Study

EU-NETVAL Medzinárodná validačná štúdia tyroidnej disrupcie

Duration: 1. 1. 2021 - 1. 1. 2023
Program: Multilaterálne - iné
Project leader: Dr.rer.nat., Ing. Kanďárová Helena ERT
Annotation:Characterising, validating and standardising new non-animal methods and approaches are important steps towards their regulatory use and international adoption. Various thyroid methods, targeting different modes of action of thyroid disruption, are currently under validation by EURL ECVAM and its network of validation laboratories EU-NETVAL. Chemicals that disrupt thyroid homeostasis have the potential to be endocrine disruptors and thus associated with several adverse health effects. About EU-NETVAL: EU-NETVAL is a large network of 39 highly qualified test facilities across Europe, coordinated by the JRC to support the in vitro method validation process. It represents a wide range of expertise and competences and includes laboratories experienced in advanced in vitro procedures, biological test systems and measurement techniques.
Project web page:https://ec.europa.eu/jrc/en/eurl/ecvam/alternative-methods-toxicity-testing/eu-netval

CardioRNA - Catalysing transcriptomic research in cardiovascular disease

Katalýza transkriptomického výskumu kardiovaskulárnych ochorení

Duration: 3. 10. 2018 - 2. 10. 2022
Program: COST
Project leader: doc. RNDr. Barteková Monika PhD.
Annotation:This Action aims to create an interdisciplinary network to accelerate the understanding of transcriptomics in cardiovascular disease (CVD) and further the translation of experimental data into usable applications to improve personalized medicine in this field. CVD remains the leading cause of death worldwide and, despite continuous advances, better diagnostic and prognostic tools, as well as therapy, are needed. The human transcriptome, which is the set of all RNA produced in a cell, is much more complex than previously thought and the lack of dialogue between researchers and industrials and consensus on guidelines to generate data make it harder to compare and reproduce results. Currently, there is no network to address the complexity of transcriptomics in CVD, offering an advantage to this Action. It aims to provide opportunities for collaboration between stakeholders from complementary backgrounds, allowing the functions of different RNAs and their interactions to be more rapidly deciphered in the cardiovascular context for translation into the clinic. This Action will generate grant proposals to advance understanding of the transcriptome’s role in CVD and to translate findings into clinical applications, thus fostering personalized medicine and meeting a current public health challenge. CardioRNA will refine guidelines for transcriptomics investigations in CVD to increase reproducibility of results, facilitating clinical product development. It will disseminate knowledge and allow capacity-building through different types of meetings, prioritizing students and early career investigators. Thus, this Action will advance studies on cardiovascular transcriptomics, generate innovative projects and consolidate the leadership of European research groups in the field.

LOGIC LAB - Molecular logic lab-on-a-vesicle for intracellular diagnostics

Molecular logic lab-on-a-vesicle for intracellular diagnostics

Duration: 1. 11. 2018 - 31. 10. 2022
Program: Horizont 2020
Project leader: RNDr. Mach Mojmír PhD.
Annotation:A dysfunction of cells lining the inner walls of blood vessels, i.e. the endothelium, is the primary cause of many lifestyle related diseases. According to the WHO, those diseases accounted for 60% of all deaths worldwide in 2005. Tailor-made diagnostic tools for early and reliable identification of endothelial dysfunction are urgently needed both in fundamental research and clinical routine, respectively. The Marie Skłodowska-Curie action LOGIC LAB objects to develop and characterize innovative molecular logic gates that can be applied as advanced diagnostic tools for parallel analyte sensing in live mammalian cells. Thereby, providing a unique method to discover endothelial dysfunction and the onset of diseases much easier and earlier than so far. LOGIC LAB creates a multi-faceted and multi-sectoral research environment for the next generation of scientists in order to establish a novel type of molecular logic sensors that reliably operate in biological media – a crucial requirement for their application i.e. as rapid and easy-to-handle tools for intracellular diagnostics. With excellent cross-disciplinary scientific and complementary training provided in the network, we aim to educate highly-skilled young scientists in the fields of chemistry, physics and biology, who will significantly strengthen the international research community in the domain of molecular logic sensing. Thus, in the long term, LOGIC LAB aims to finally bridge the gap between lab bench and biological or medical practice. It is this gap, that so far prevents a wide-ranging use of existing molecular logic gates e.g. for the diagnosis of lifestyle-associated diseases.

Anti-inflammatory effects of natural compounds isolated from Vietnam medicinal plants

Protizápalový účinok prírodných látok izolovaných z vietnamských liečivých rastlín

Duration: 1. 1. 2020 - 31. 12. 2022
Program: Bilaterálne - iné
Project leader: PharmDr. Bauerová Katarína PhD., DrSc.

EU-CARDIOPROTECT - Realising the therapeutic potential of novel cardioprotective therapies

Realizácia terapeutického potenciálu nových kardioprotektívnych terapií

Duration: 19. 10. 2017 - 18. 4. 2022
Program: COST
Project leader: MUDr. Ravingerová Táňa DrSc., FIACS
Annotation:The proposed COST Action will set up a pan-European Research Network of leading experts in cardioprotection, to jointly develop new initiatives and new strategies for finding innovative and more effective approaches to cardioprotection and for optimizing the pre-clinical and clinical evaluation of new cardioprotective therapies, so as to improve their translation into the clinical setting for patient benefit. The COST Action will co-ordinate and strengthen European research in the field of cardioprotection and accelerate scientific progress through the dissemination and sharing of new therapeutic targets, among network members and industrial partners, thereby facilitating the discovery of new cardioprotective therapies. By utilizing the joint expertise of different European network members we will investigate factors which confound the efficacy of new cardioprotection therapies including comorbidities (such as age, diabetes, and hypertension) and co-medications (such as anti-platelet therapies, statins and beta-blockers). Finally, we will set up a European network of research centers for multi-center laboratory testing of new cardioprotective therapies using small and large animal models of acute IRI in order to select those therapies most likely to succeed in the clinical setting. All aspects of this COST Action proposal require a critical mass of partners across a wide geographic distribution across Europe in order to deliver the objectives outlined in this proposal. The discovery of novel signaling pathways and targets underlying cardioprotection both within and outside the cardiomyocyte (WG1 NEW TARGETS), and the testing of different combinations of cardioprotective therapy (WG2 COMBINATION THERAPY) requires investigators with different experience and expertise across Europe. The ability to test the effect of confounders of cardioprotection (WG3 CONFOUNDERS) requires the expertise of different partners in the different co-morbidities and testing of co-medications. Finally, the most important objective of this COST Action proposal, requires the setting up of a Europe-wide research network for (a) multicenter testing of novel cardioprotective therapies using small and large animal models (WG4 CONSORTIUM) and (b) testing of novel cardioprotective therapies in proof-of-concept clinical studies and optimization of multi-center clinical outcome cardioprotection studies. By definition this requires a critical mass of research partners distributed across Europe.

SKPTPHARMACOL - Collaboration on a complex pharmacological assessment of inflammatory diseases of the musculo-skeletal system and gastrointestinal tract on experimental animal models

Spolupráca na komplexnom hodnotení farmakologického ovplyvnenia zápalových ochorení pohybového aparátu a gastrointestinálneho traktu na experimentálnych zvieracích modeloch

Duration: 1. 1. 2019 - 31. 12. 2021
Program: Bilaterálne - iné
Project leader: PharmDr. Bauerová Katarína PhD., DrSc.

Train -SafeMDs - Training Network for improving of safety of medical devices - focus on oral cavity

Školiaca sieť zameraná na zvýšenie bezpečnosti zdravotníckych pomôcok - fokus na ústnu dutinu

Duration: 1. 1. 2020 - 31. 8. 2022
Program: Multilaterálne - iné
Project leader: Dr.rer.nat., Ing. Kanďárová Helena ERT
Annotation:The TraiN-SafeMDs (i.e. Training Network for improving knowledge on the safety of medical devices) project brings together the unique expertise of the Czech National Institute of Public Health located in Prague (NIPH), the expertise of the Centre of Experimental Medicine in Bratislava (CEM) and the Austrian Institute of Technology in Vienna (AIT). The research team of the project has extensive expertise in tissue engineering of models of oral epithelium and/or in safety testing of different MD materials. The project also aims into the training of PhD students and early career scientist in the use of in vitro methods for the safety assessment of MDs.
Project web page:https://www.medicaldevicessafety.com/

ONTOX - Ontology-driven and artificial intelligence-based repeated dose toxicity testing of chemicals for next generation risk assessment

Testovanie opakovanej toxicity chemických látok na základe ontológie a umelej inteligencie za účelom hodnotenia rizík metódami NGRA

Duration: 1. 5. 2021 - 1. 5. 2026
Program: Horizont 2020
Project leader: Dr.rer.nat., Ing. Kanďárová Helena ERT
Annotation:The vision of the ONTOX project is to provide a functional and sustainable solution for advancing human risk assessment of chemicals without the use of animals in line with the principles of 21st century toxicity testing and next-generation risk assessment. Specifically, ONTOX will deliver a generic strategy to create innovative new approach methodologies (NAMs) in order to predict systemic repeated dose toxicity effects that, upon the combination with tailored exposure assessment, will enable human risk assessment. This strategy can be applied to any type of chemical and systemic repeated dose toxicity effect. However, for proof-of-concept purposes, focus will be put on 6 specific NAMs addressing adversities in the liver (steatosis and cholestasis), kidneys (tubular necrosis and crystallopathy) and developing brain (neural tube closure and cognitive function defects) induced by a variety of chemicals, including from the pharmaceutical, cosmetics, food and biocide sectors. The 6 NAMs will each consist of a computational system based on cutting-edge artificial intelligence (AI) and will be primarily fed by available biological/mechanistic, toxicological/ epidemiological, physico-chemical and kinetic data. Data will be consecutively integrated in physiological maps, quantitative adverse outcome pathway networks and ontology frameworks. Data gaps, as identified by AI, will be filled by targeted state-of-the-art in vitro and in silico testing. The 6 NAMs will be evaluated and applied in collaboration with industrial and regulatory stakeholders in order to maximise end-user acceptance and regulatory confidence. This is anticipated to expedite implementation in risk assessment practice and to facilitate commercialisation. ONTOX will have a deep and long-lasting impact at many levels, in particular by consolidating Europe's world-leading position regarding the development, exploitation, regulation and application of animal-free methods for human risk assessment of chemicals.
Project web page:www.ontox-project.eu

National Projects

Prenatal programming of adult diseases: treatment and prevention of outcomes of gestational hypoxia in rat offspring

Prenatálne programovanie chorôb v dospelosti: možnosti terapie a prevencie následkov prenatálnej hypoxie u potomstva potkanov

Duration: 1. 1. 2020 - 31. 12. 2023
Program: VEGA
Project leader: RNDr. Mach Mojmír PhD.
Annotation:Hypoxia during pregnancy, labor or early life stage is a major determinant of neurological morbidity and mortality in the neonatal period. In the last decade the fetal origin of chronic adult diseases was proposed as the most important factor in genesis of diabetes and hypertension in adulthood. The scientists showed that malnutrition, and inadequate oxygen supply during embryofetal development may lead to the inadequate apoptosis/necrosis, and caused maldevelopment of the organs responsible for regulation blood pressure, glucose, or improper brain wiring. Although the understanding of perinatal asphyxia-related pathophysiology is gradually increasing, limited therapeutic options are available to prevent or even mitigate the devastating process that unfolds after injury. Mitochondria-targeted antioxidants (MTA) are one of the most important therapies for providing neuroprotection in cerebral ischemia. The aim of the project will be to explore the possibilities of using MTA in late gestational hypoxia model.

Centre for biomedical research - BIOMEDIRES - II. stage

Centrum pre biomedicínsky výskum – BIOMEDIRES - II. etapa

Duration: 12. 3. 2020 - 11. 3. 2024
Program: Štrukturálne fondy EÚ Výskum a vývoj
Project leader: doc. RNDr. Pecháňová Oľga DrSc.

Indole-1-acetic acid derivatives as aldose reductase inhibitors: structure – activity relationships

Deriváty kyseliny 1-indoloctovej ako inhibítory aldózareduktázy: vzťah štruktúry a aktivity

Duration: 1. 1. 2018 - 31. 12. 2021
Program: VEGA
Project leader: Ing. Šoltésová Prnová Marta PhD.

Electrophysiological correlates and determinants of visual working memory precision

Elektrofyziologické koreláty a determinanty presnosti vizuálnej pracovnej pamäti

Duration: 1. 1. 2019 - 31. 12. 2021
Program: VEGA
Project leader: MUDr. Riečanský Igor PhD.

Experimental therapy of neonatal hypoxic-ischemic encephalopathy (nHIE): potentiation of hypothermic neuroprotection by melatonin in newborn rats

Experimentálna liečba neonatálnej hypoxicko-ischemickej encefalopatie (nHIE): potenciácia hypotermickej neuroprotekcie melatonínom u novorodených potkanov

Duration: 1. 1. 2020 - 31. 12. 2023
Program: VEGA
Project leader: RNDr. Juránek Ivo PhD., DrSc.
Annotation:Neonatal hypoxic-ischemic encephalopathy (nHIE) is among most serious causes of mortality and morbidity in newborns. Efficacy of current nHIE treatment is rather low. Routinely used therapeutic hypothermia (HT) is only partially effective. To augment hypothermic neuroprotection, drugs like erythropoietin, anticonvulsants, antioxidants and inert gases are tested. In this project, using newborn rats, we will study possible augmentation of hypothermia effect by combining HT with melatonin (MEL)-derived antioxidants. We will assess brain damage and efficacy of each intervention by various techniques, including noninvasive in vivo MRI and MRS, histology and neurobehavioral testing. Novelty of the project lies in testing our idea that MEL-derivative possessing antioxidative properties 100 fold higher than MEL will be more effective in potentiating the hypothermic effect than MEL itself. Anticipated results may help understand better nHIE mechanisms and to propose new strategies to treat birth asphyxia effectively.

-

Experimentálna štúdia pôsobenia materskej depresie a antidepresívnej liečby počas gravidity a laktácie na zdravie matky a vývin potomstva.

Duration: 1. 1. 2019 - 31. 12. 2022
Program: VEGA
Project leader: RNDr. Dubovický Michal CSc.

-

Experimentálny infarkt myokardu: príspevok hypertenzie a obezity, účinok inhibítora toll-like receptorov.

Duration: 1. 1. 2019 - 31. 12. 2022
Program: VEGA
Project leader: doc. RNDr. Pecháňová Oľga DrSc.

-

Hodnotenie a porovnanie protizápalovej a antioxidačnej účinnosti karotenoidov in vitro a in vivo pomocou modelov chronických zápalových ochorení.

Duration: 1. 1. 2020 - 31. 12. 2022
Program: VEGA
Project leader: PharmDr. Bauerová Katarína PhD., DrSc.

Bio-compatibility assessment of medical devices and novel medical device materials using in vitro methods based on 3D reconstructed human tissue models.

Hodnotenie biologickej kompatibility zdravotníckych pomôcok (ZP) a innovativnych materiálov pre výrobu ZP s využitím in vitro metód založených na 3D rekonštruovaných modeloch ľudského tkaniva.

Duration: 1. 1. 2020 - 31. 12. 2023
Program: VEGA
Project leader: Dr.rer.nat., Ing. Kanďárová Helena ERT

Safe-MDs - In vitro biocompatibility testing of medical devices (MDs) and new generation bio-materials for MDs

In vitro hodnotenie bio-kompatibility zdravotníckych pomôcok (ZP) a inovatívnych bio-materiálov pre ZP

Duration: 1. 7. 2020 - 30. 6. 2024
Program: APVV
Project leader: Dr.rer.nat., Ing. Kanďárová Helena ERT
Annotation:Medical devices (MDs) have an irreplaceable role in the healthcare of the 21st century. The term ‘medical device’ covers a broad spectrum of products that are crucial in diagnosis and treatment, disease prevention and improving the quality of life of people suffering from disabilities or injuries. MD must not cause adverse effects and must demonstrate bio-compatibility with the tissues in the patient’s body. Most of the MDs' bio-compatibility assessments are still conducted in animals. However, thanks to the advances in cell and 3D tissue engineering and due to the accelerated progress of validation of alternative methods, the MD regulations also utilize in vitro tests, as demonstrated recently by the adoption of the in vitro reconstructed human epidermis (RhE) test for intra-cutaneous testing into the ISO standard 10993-23. The presented research proposal focuses on the development of in vitro methods for biocompatibility assessment of medical devices (MDs) and innovative materials to be used as MDs polymers and that are intended for the use in the oral and vaginal cavities or on/in ocular epithelium.

TOXINOVAGE - Innovative approaches in toxicology of ageing

Inovatívne prístupy v toxikológii starnutia

Duration: 1. 7. 2019 - 30. 6. 2023
Program: APVV
Project leader: Ing. Račková Lucia PhD.

-

Kardioprotektívny potenciál TRP kanálov: úloha v remodelácii, zápale a vápnikovej dysregulácii

Duration: 1. 1. 2021 - 31. 12. 2024
Program: VEGA
Project leader: MUDr. Ravingerová Táňa DrSc., FIACS

SEMSTIM - Cognitive and brain mechanisms of semantic processing

Kognitívne a mozgové mechanizmy sémantického spracovania informácií

Duration: 1. 7. 2020 - 30. 6. 2024
Program: APVV
Project leader: MUDr. Riečanský Igor PhD.

Cognitive and neurophysiological determinants of semantic cognition

Kognitívne a neurofyziologické determinanty sémantickej kognície

Duration: 1. 1. 2020 - 31. 12. 2022
Program: VEGA
Project leader: Mgr. Marko Martin PhD.
Annotation:Semantic system creates and structures knowledge that guides adaptive cognition and behavior. The ability to access and use relevant semantic information is underpinned by a number of neurocognitive mechanisms, which are poorly understood. Our research aim is to investigate the cognitive systems and mechanisms that regulate the retrieval of information from semantic memory. For this purpose, we will use systematic manipulation of cognitive load and non-invasive transcranial electrical stimulation (tES) of the prefrontal brain cortex. Using these experimental approaches, we will inspect the role of executive control in semantic retrieval and provide a detailed description of the fundamental cognitive and neurophysiological determinants of semantic retrieval functions.
Project web page:https://www.researchgate.net/project/Cognitive-and-neurophysiological-determinants-of-semantic-cognition

Mesenteric perivascular fat and its specific role in regulation of intestinal circulation in rats with different feeding regimens

Mezenterický perivaskulárny tuk a jeho špecifická úloha v regulácii črevnej cirkulácie u potkana pri rôznych režimoch príjmu potravy

Duration: 1. 1. 2021 - 31. 12. 2023
Program: VEGA
Project leader: Mgr. Zemančíková Anna PhD.
Annotation:This project will solve questions to what extent and in which way might the different diet and feeding regimens (intermittent, ad libitum, high fat diet) influence the regulation of smooth muscle activity of rat mesenteric arteries by perivascular fat, and which signal mechanisms participate on these processes. Besides healthy individuals, obese rats will be used in which the vascular sympathetic tone is enhanced and its activity is specifically regulated by mesenteric adipose tissue. On isolated conduit and small mesenteric arteries, the effect of mesenteric fat on their reactivity, biochemical processes, and function of perivascular nerves will be measured. The results of this study should be aimed to respond the question how much these processes might be involved in ingestion/utilization of food in subjects under different dietary regimens, and subsequently in regulation of body weight and visceral adiposity in individuals negatively influenced by obesity.

Mitochondria as a key effector in processes of cardioprotective intervention

Mitochondrie ako kľúčový efektor v procesoch kardioprotektívnych intervencií

Duration: 1. 1. 2018 - 31. 12. 2021
Program: VEGA
Project leader: Ing. Ferko Miroslav PhD.

Modulation of dysregulation of extracellular matrix and intercellular communication as a heart protection from its functional failure

Modulácia dysregulácie extracelulárnej matrix a medzibunkovej komunikácie ako protekcia srdcového svalu pred jeho funkčným zlyhaním

Duration: 1. 1. 2019 - 31. 12. 2022
Program: VEGA
Project leader: RNDr. Szeiffová Bačová Barbara PhD.
Annotation:Cardiovascular diseases are accompanied by extracellular matrix remodeling and fibrosis associated with impaired myocardial gap junction communication, what subsequently results in the development of heart failure and malignant arrhythmias. Cardiac fibrosis is one of the major problems in medicine with no effective treatment. We aimed in this project to characterize key factors involved in profibrotic signaling in rats with hypertension, altered thyroid status, post-infarction injury and to examine the possibilities of pharmacological and non-pharmacological modulation of these profibrotic factors. This approach should reveal key signaling pathways and proteins whose modulation could reverse or stop fibrosis process and then improve intercellular communication in the myocardium. Project results should contribute to new knowledge potentially usable in clinical practice as well.

Nitroso-sulphide signal pathway - novel regulator vasoactive effects in different types of arterial hypertension

Nitrózo-sulfidová signálna dráha - nové regulačné vazoaktívne účinky v rôznych modeloch artériovej hypertenzie

Duration: 1. 1. 2018 - 31. 12. 2021
Program: VEGA
Project leader: RNDr. Čačányiová Soňa PhD.
Annotation:Nitric oxide (NO) and hydrogen sulphide (H2S) belong to important gaseous molecules engaged to the regulation of arterial tone in normotensive conditions. NO and H2S interaction includes a formation of new products which are part of an original nitroso-sulphide signalling pathway. Our previous experiments in Wistar rats demonstrated that these new signal molecules triggered a specific vasoactive response, different from the effect evoked by NO and H2S. In condition of arterial hypertension, the vasoactive effects of the novel signalisation have not been described yet. The aim of this project is to characterise the role of NO and H2S as well as of the nitroso-sulphide signalling pathway in different animal models of hypertension: essential (SHR), NO-deficient and also metabolic syndrome (hypertriglyceridemia – HTG). A simultaneous investigation of human vessels isolated from patients with hypertension and dyslipidemia represents an appropriate way how to associate results of basic research with clin. practise.

Novel compounds in prevention and treatment of diseases caused by glucose toxicity

Nové látky pre prevenciu a terapiu ochorení spôsobených toxicitou glukózy

Duration: 1. 1. 2018 - 31. 12. 2021
Program: VEGA
Project leader: RNDr. Májeková Magdaléna PhD.
Annotation:In the long term lasting plasma glucose level may affect the course of physiological processes through numerous metabolic pathways. A polyol pathway ranks among the important mechanisms of glucose toxicity and its main enzyme – aldose reductase – is a frequent target in design of drugs reducing the progress of chronic diabetic complications. Another target could be introduced by calcium homeostasis in cells, as the cytosolic calcium level is an important factor for many physiological processes, e.g. the insulin secretion. A modulation of calcium pump SERCA becomes another mechanism for the manifestation of glucose toxicity. The aim of our project is to find new compounds with polypharmacological effect, by means of combinatorial library of potential aldose reductase inhibitors and actual knowledge on SERCA activity.

-

Nové metódy prevencie a liečby oxidačného stresu, ischemicko-reperfúzne poškodenie a transplantácia srdca

Duration: 1. 11. 2019 - 31. 12. 2021
Program: Iné projekty
Project leader: D.h.c., Prof., MUDr. Slezák Ján DrSc., FIACS

ACE2-TXZF - New perspectives in the treatment of cardiovascular complications associated with COVID-19

Nové perspektívy v liečbe kardiovaskulárnych komplikácií spojených s COVID-19

Duration: 16. 9. 2020 - 31. 12. 2021
Program: APVV
Project leader: RNDr. Čačányiová Soňa PhD.
Annotation:Coronavirus disease 2019 (COVID-19), linked to severe acute respiratory syndrome induced by coronavirus-2 (SARS-CoV-2), was declared as a global pandemic. While respiratory failure is the major cause of mortality due to COVID-19, the great number of patients exhibit cardiovascular disorders. Understanding the underlying mechanisms of cardiovascular complications associated with COVID-19 is of the great importance to reach the effective therapy and to reduce mortality due to COVID-19. In this project we will imitate the inhibition of ACE2- mediated signalling induced by SARS-Cov-2 using highly specific ACE2 inhibitor MLN-4760. In this pharmacological model of COVID-19 in spontaneously hypertensive rats (SHR) we intend to examine the extend of MLN-4760-induced vascular damage as well as the mechanisms underlying the action of taxifoline and zofenapril, as perspective pharmacological tools for the treatment of cardiovascular complications associated with COVID-19. TX has been chosen as it was shown as promising drug-like substance inhibiting SARS-Cov-2 replication via inhibition of the main protease (Mpro). ZF is sulfhydryl-containing angiotensin converting enzyme (ACE) inhibitor spontaneously releasing hydrogen sulfide (H2S). Both substances provide several additional cardioprotective effects associated with elevated NO bioavailability and H2S release, respectively. These effects can improvefunction of the cardiovascular system via elevation of NO and H2S-mediated vasodilatation, inhibition of trombogenesis and induction of antioxidant and antiinflamatory action.

-

Nové prístupy k liečbe kachexie, zápalu a oxidačného stresu v experimentálnej artritíde: Účinok rôznych rastlinných extraktov z olivových listov, Rhodiola rosea, Tribulus terrestris a extra panenského olivového oleja

Duration: 1. 1. 2019 - 31. 12. 2021
Program: VEGA
Project leader: PharmDr. Poništ Silvester PhD.

StrokeRehab - Novel approach to post-stroke rehabilitation. A basic and translational study, aiming to restore posture control and body symmetry in post-stroke patients by sensory stimulation.

Nový prístup k rehabilitácii pacientov po cievnej mozgovej príhode. Základný a translačný výskum s cieľom zlepšiť funkciu rovnováhy a symetriu tela u pacientov po cievnej mozgovej príhode pomocou senzorickej stimulácie.

Duration: 1. 8. 2021 - 30. 6. 2025
Program: APVV
Project leader: RNDr. Bzdúšková Diana PhD.
Annotation:The main goal of this project is to investigate the pathophysiological mechanisms of keeping balance while sitting and standing in post-stroke patients and to define the rationale for interventions based on visual and proprioceptive stimulations for enhancing balance, impaired trunk mobility and trunk asymmetry. To achieve this, we will use the original method for rehabilitation and monitoring of patients as well as specialized devices together with softwares which we developed during our previous project APVV-16-0233. Stroke is a major health problem, especially considering that post-stroke patients typically have residual impairments to their motor and sensory functions directly affecting their postural system. Keeping balance while sitting up in bed or on a chair is with high probability the first thing a therapist addresses to patients. Controlled trunk function is an important and essential component for standing balance, gait and other daily activities. The voluntary movements of the trunk clearly reveal the postural and movement asymmetry of the upper part of the body. The asymmetric position is most often characterized by one-sided tilt of the trunk or its reduced mobility to one side. We aim to advance knowledge on the abnormal posture due to impairment of dynamic balance as a consequence of stroke, and to exploit visual and proprioceptive stimulations in order to improve posture and trunk asymmetry in post-stroke patients. Finally we will evaluate efficiency of rehabilitation procedures using two different approaches: i) by recording of the centre of pressure using force plate and ii) by recording of trunk tilts using inertial sensors.

Heart protection in situations of excessive formation of oxygen and nitrosyl radicals: Molecular hydrogen as a new potential therapeutic tool?

Ochrana srdca v situáciách nadmernej tvorby kyslikových a nitrozylových radikálov: Molekulárny vodík ako nový potenciálny therapeutický nástroj?

Duration: 1. 1. 2018 - 31. 12. 2021
Program: VEGA
Project leader: Mgr. Kura Branislav PhD.
Project web page:https://evega.minedu.sk/e-vega/(S(yi1zctb4lxjmuf55ntk1jfbm))/default.aspx

Are connexin channels involved in extracellular matrix remodeling of overloaded heart?

Podieľajú sa konexinové kanály v preťaženom srdcovom svale na extracelulárnej remodelácii?

Duration: 1. 1. 2020 - 31. 12. 2023
Program: VEGA
Project leader: RNDr. Tribulová Narcisa DrSc.
Annotation:Cardiac connexin (Cx) channels that are localized at the gap junctions in intercalated discs ensure electrical and molecular signals propagation among cardiomyocytes. Such direct intercellular signaling is essential for synchronized heart contraction. Cardiovascular diseases in humans as well as in animal models are accompanied by abnormal Cx43 expression and its enhanced localization to the lateral sides of the cardiomyocytes. Consequently, it deteriorates synchronized heart function and increase a risk for malignant arrhythmias. Based on general knowledge and our studies we hypothesize that laterally localized Cx43 channels might transmit signals from cardiomyocytes into extracellular space and by this way contribute to adverse extracellular matrix remodeling. Intention of the project is to reveal the possible implication of Cx43 channels in modulation of extracellular space in diseased heart. It may stimulate to search novel approaches in protection from cardiac dysfunction and arrhythmias.

Comparison of antidepressant effects of natural psychoplastogen and an mTOR activator in animal model of depression

Porovnanie antidepresívnych účinkov prírodného psychoplastogénu a aktivátora mTOR v animálnom modeli depresie

Duration: 1. 1. 2021 - 31. 12. 2023
Program: VEGA
Project leader: RNDr. Vranková Stanislava PhD.
Annotation:Increasing prevalence of depression presents an unavoidable problem for psychiatry. Existing antidepressants exert their effect only after several weeks of continuous treatment. In addition, their serious side effects in one-third of patients call for urgent action. Recent advances have given rise to the concept of psychoplastogens. These compounds are capable of fast structural and functional rearrangement of neural networks by targeting mechanisms previously implicated in the development of depression. Furthermore, evidence shows that they exert potent acute and long-term positive effects. Several of them are naturally occurring compounds, such as 7,8-dihydroxyflavone (7,8-DHF). The aim of our study is to investigate the effects of 7,8-DHF and NV-5138, an mTOR (mammalian target of rapamycin) activator, and their combinations, on the development of depressive-like symptoms in animal model. Results of this project will contribute to elucidating the pathogenesis of depression and their treatment possibilities.

Postural threat in virtual reality in adults with height intolerance

Posturálna hrozba v prostredí virtuálnej reality u ľudí so strachom z výšky

Duration: 1. 1. 2022 - 31. 12. 2024
Program: VEGA
Project leader: RNDr. Bzdúšková Diana PhD.
Annotation:Virtual reality (VR) is suitable for evaluating postural and psychophysiological parameters in different situations and different populations. Fear of height and subsequent fall causes limitations in daily living and avoidance of any height, which represents a postural threat. A possible solution to relieve the stress and anxiety is a stance on an elevated platform in VR, which can repeatedly create a real-life experience that the subject gradually becomes accustomed to, but in safe and controlled conditions. Intervention can be enhanced before exposure to height by transcranial stimulation (tDCS) of the cerebellum, which plays a significant role in postural control. The aim of the project is to gain new knowledge about postural and psychophysiological reactivity during the postural threat in VR and to explore it immediately after tDCS. The obtained results may be beneficial for the rehabilitation of patients with balance disorders, people with height intolerance, and the elderly at risk of falls.

The use of mass spectrometry for comparative study of different rats strains glycoprofiles within metabolic disturbances intervention

Použitie hmotnostnej spektrometrie na porovnanie glykoprofilov rôznych kmeňov potkanov v intervencii metabolických porúch

Duration: 1. 1. 2021 - 31. 12. 2023
Program: VEGA
Project leader: Ing. Brnoliaková Zuzana PhD.
Annotation:Metabolic syndrome (MetS) defines a cluster of interrelated risk factors for diabetes mellitus. Glycobiology is helping in search for biomarkers of severe diseases, the bioanalytical metods were patented. We hypothesize: the glycomic profiling of blood sera has the potential in MetS diagnostics. The goals are to acquire glycomic profiles, by means of mass spectrometry, derived from blood sera of different rats strains; to characterize their composition; to correlate with pathophysiology; to evaluate the differences with respect to the glycosylation changes (sialylation, fucosylation). In vivo: to realize the study with nutritional intervention; to evaluate the effect of allimentary habits preferences on the metabolic condition. In vitro: to investigate the impact of key mechanisms of MetS in association with cellular glycoprofile induced changes. As the output: might be the model glycomic tool for basic research appointed to test therap. approaches with perspespective for clinical research recommendations.

-

Prepojenie niektorých foriem bunkovej smrti nekrotického fenotypu: signalizácia a multicieľový nástroj pre zmiernenie poškodenia srdca v dôsledku ischémie?

Duration: 1. 1. 2020 - 31. 12. 2023
Program: VEGA
Project leader: MUDr. Ravingerová Táňa DrSc., FIACS

-

PROTEKCIA KARDIOVASKULÁRNEHO SYSTÉMU PRI EXPERIMENTÁLNEJ HYPERTENZII A ZLYHANÍ SRDCA DUÁLNOU INHIBÍCIOU NEPRILYZÍNU A AT1 RECEPTOROV PRE ANGIOTENZÍN II: POROVNANIE S ACE-INHIBÍCIOU A MELATONÍNOM

Duration: 1. 1. 2019 - 31. 12. 2022
Program: VEGA
Project leader: doc. RNDr. Pecháňová Oľga DrSc.

SVBENMKVS - Investigation of endotoxin effects on mechanosensoric complex in the heart of normotensive rats.

Skúmanie vplyvu bakteriálneho endotoxínu na mechanosenzorický komplex v srdci.

Duration: 1. 12. 2020 - 31. 12. 2023
Program: VEGA
Project leader: RNDr. Okruhlicová Ľudmila CSc.

TraiN-SafeMDs - Training Network for improving of safety of medical devices - focus on oral cavity

Školiaca sieť zameraná na zvýšenie bezpečnosti zdravotníckych pomôcok - fokus na ústnu dutinu

Duration: 1. 3. 2020 - 31. 12. 2022
Program: APVV
Project leader: Dr.rer.nat., Ing. Kanďárová Helena ERT
Annotation:Medical devices (MDs) have irreplaceable role in modern healthcare. The term ‘medical device’ covers a broad spectrum of products that are crucial in diagnosis and treatment, disease prevention and improving the quality of life of people suffering from disabilities or injuries. MDs used in the oral cavity are usually those helping in the treatment of aphthae or canker sores irritations and lesions of the oral mucosa by forming a barrier that adheres to the oral mucosa and promotes healing. Dental materials and dental prosthetic devices are also an important group of MDs with apparent contact with oral mucosa. Most of the MDs bio-compatibility assessments is still conducted in animals. However, thanks to the advances in cell and 3D tissue engineering and due to the accelerated progress in validation of alternative methods, the MD regulations are also in vitro tests, as demonstrated recently by the adoption of the in vitro reconstructed epidermis test for intra-cutaneous testing into the ISO standard 10993-23 (Kandarova et al.,/DeJong et al., 2018). Biocompatibility testing of MDs is based on the toxicity assessment of extracts from MDs, that are in fact highly diluted solutions of potential irritants. Therefore any already validated in vitro tests and prediction models must be fine-tuned to achieve different levels of sensitivity for this specific type of materials. The proposed project builds on the practical experiences gained in the validation study for intra-cutaneous testing of MDs in which the research teams from Slovakia and Czech republic participated between 2012-2018. The current project will use 3D reconstructed tissues of oral/buccal epithelia and cell cultures with the origin in oral cavity with the aim to develop highly sensitive testing strategy for local tolerance testing in vitro. The project also aims into the training of PhD students and early career scientist in the use of in vitro methods for the safety assessment of MDs.
Project web page:medicaldevicessafety.com

HNOSES - Study of biological effects of H2S/NO/selenium products and molecular mechanisms of their actions

Štúdium biologických účinkov produktov H2S/NO/selénovej interakcie a molekulárne mechanizmy ich pôsobenia

Duration: 1. 7. 2020 - 30. 6. 2024
Program: APVV
Project leader: RNDr. Čačányiová Soňa PhD.
Annotation:Reactive sulfur (RSS), nitrogen (RNS) and selenium species (RSEs) are groups of simple chemical molecules of radical or non-radical nature, which interact with cellular components and thereby influence various biological processes. The study of biological effects of RSS, RNS and RSeS and their mutual interactions is important for the understanding of their biological roles, moreover for the potential application of these species in medicine. Our studies of the reactive species interaction in the last 3 years showed that: - products of hydrogen sulfide (H2S) and polysulfides (H2Sn, n≥2) interaction with nitric oxide (NO) or selenium compounds (R-Se) significantly affect oxygen radicals concentrations, hydroperoxide cleavage, DNA damage, rat blood pressure and tension/relaxation of isolated aorta.- H2S and H2S2 interact with tetracycline antibiotics, mainly doxycycline (DOXY) and thereby produce/inhibit superoxide and hydroxyl radicals and induce/inhibit DNA damage These findings imply the possibility that reactive oxygen species (ROS) and other H2S/NO/R-Se interaction products affect (patho)physiological functions in living organisms. In the project´s aims we will build on the previous findings and investigate following new hypotheses: 1) Do mixtures (H2Sn/R-Se, H2Sn/R-Se/NO alebo H2Sn/DOXY) produce ROS or other biologically active compounds? 2) Are these products responsible for production/inhibition of radicals, cleavage of hydroperoxides and induction/inhibition of DNA damage? 3) Do interaction products affect ferroptosis or intracellular calcium concentration in cells? 4) Do these products affect rat blood pressure, arterial pulse waveform and tension of isolated arteries? The aim of this project is to investigate the chemical biology, activity and effects of the interaction products on cellular, organ and whole-organism level. These findings may contribute to the development of novel therapeutic interventions based on the modulation of cellular redox biology.

Study of new mechanisms of cardioprotection against ischemia-reperfusion injury of the heart: role of extracellular vesicles, non-coding RNAs and impact of metabolic co-morbidities on these mechanisms

Štúdium nových mechanizmov kardioprotekcie voči ischemicko-reperfúznemu poškodeniu srdca: úloha extracelulárnych vezikúl, nekódujúcich RNA a vplyv metabolických komorbidít na tieto mechanizmy

Duration: 1. 1. 2020 - 31. 12. 2023
Program: VEGA
Project leader: doc. RNDr. Barteková Monika PhD.
Annotation:Ischemic heart disease and myocardial infarction represent major diseases associated with ischemia-reperfusion (I/R) injury of the heart. Despite several powerful cardioprotective interventions against I/R injury including endogenous (e.g. ischemic conditioning) as well as exogenous ones including treatment with natural antioxidants, have been proposed, molecular mechanisms of cardioprotection are not fully clarified so far; moreover, there are serious translational gaps in transferring cardioprotective interventions into clinics due to comorbidities present in real patients suffering from cardiac I/R injury. The aim of the present project is to uncover the role of extracellular vesicles as new players in cardioprotection, to identify particular non-coding RNAs involved in cardioprotection, and to explore the effect of metabolic co-morbidities on molecular mechanisms and efficiency of cardioprotection, altogether in the sake of effective transfer of experimental knowledge to human personalized medicine.

Study of triggering factors and signal transduction mechanisms induced by noninvasive adaptive interventions in rats aimed to protect myocardium against schemia

Štúdium spúšťacích faktorov a mechanizmov prenosu signálu indukovaných neinvazívnymi adaptačnými intervenciami v organizme potkana za účelom ochrany myokardu pred schémiou

Duration: 1. 1. 2018 - 31. 12. 2021
Program: VEGA
Project leader: MUDr. Ravingerová Táňa DrSc., FIACS
Annotation:Cardiovascular diseases are one of the leading causes of mortality in modern society. They are predicted to rise over the coming decades, due to aging population, longer survival of patients after myocardial infarction, and incidence of civilization diseases. Research pointed out to the protective effects of adaptive phenomenon of ischemic preconditioning (IPC) and its novel clinically acceptable and safer forms. Currently, cellular mechanisms activated by stimuli like exercise, acute hypoxia and PC of the remote organ are not yet completely elucidated as compared with classiccal IPC. For that reason, several pathological animal models (myocardial ischemia, hypertension, d. mellitus, dyslipidemia) will be used. Acute and longer lasting adaptive interventions will be tested using relevant methodology (combination of physiological, morphological and biochemical techniques). The results obtained in this project may lead to development of novel or modified therapeutic strategies to manage myocardial ischemia

The study of structural changes of complex glycoconjugates in the proces of inherited metabolic and civilization diseases

Štúdium štruktúrnych zmien komplexných glykokonjugátov v procese dedičných metabolických a civilizačných ochorení

Duration: 1. 3. 2021 - 30. 6. 2023
Program: Štrukturálne fondy EÚ Výskum a vývoj
Project leader: Ing. Brnoliaková Zuzana PhD.

Effects of natural and synthetic compounds on oxidative damage of biomacromolecules. Pro-oxidative and antioxidative mechanisms.

Účinky prírodných a syntetických zlúčenín pri oxidačnom poškodení biomakromolekúl. Pro- a antioxidačné mechanizmy.

Duration: 1. 1. 2019 - 31. 12. 2022
Program: VEGA
Project leader: RNDr. Valachová Katarína PhD.

-

Účinok bakteriálneho endotoxínu na komunikačné spojenia ciev srdca za podmienok hypertenzie.

Duration: 1. 1. 2019 - 31. 12. 2022
Program: VEGA
Project leader: Ing. Frimmel Karel PhD.

The role of macroautophagy and chaperone-mediated autophagy (CMA) in the responses and adaptation of animal cells to doxorubicin-induced effects

Úloha makroautofágie a autofágie sprostredkovanej šaperónmi (CMA) v odpovediach a v adaptácii živočíšnych buniek na účinky vyvolané pôsobením doxorubicínu

Duration: 1. 1. 2021 - 31. 12. 2024
Program: VEGA
Project leader: RNDr. Barančík Miroslav DrSc.

The role of matrix metalloproteinases in pathophysiology of cardiovascular system diseases and their relation to cellular redox signaling.

Úloha matrixových metaloproteináz v patofyziológii ochorení kardiovaskulárneho systému a ich vzťah k bunkovej redoxnej signalizácii.

Duration: 1. 7. 2019 - 30. 6. 2023
Program: APVV
Project leader: RNDr. Barančík Miroslav DrSc.

MIRCVD - The role of miRNAs in the onset and progression of cardiovascular diseases - new approach to the protection of the heart in situations of increased production of reactive oxygen species

Úloha miRNA pri vzniku a priebehu kardiovaskulárnych ochorení - nové prístupy ochrany srdca v situáciách zvýšenej produkcie reaktívnych foriem kyslíka

Duration: 1. 7. 2020 - 30. 6. 2024
Program: APVV
Project leader: Mgr. Kura Branislav PhD.
Annotation:Despite progress in prevention, diagnosis and treatment, cardiovascular disease (CVD) is one of the highest morbidity and mortality rates in the world. World Health Organization statistics suggest that in 2030 approximately 23.6 million people will die of CVD, particularly from heart failure and myocardial infarction. One of the most common causes of many CVDs is excessive production of reactive oxygen species (ROS). These arise naturally in all organisms that gain energy by oxidizing substrates, but are also the result of various exogenous effects, such as radiation or air pollution. ROSs affect all types of cells in the body. By their activity, they cleave electrons from the molecules, making the surrounding molecules unstable and subsequently damaging other surrounding molecules. This damage process leads to cell apoptosis, tissue damage and pathological processes and diseases. At present, many experimental works emphasize the use of microRNAs (miRNAs) in diagnostics and potentially also in CVD therapy. miRNA is a group of short non-coding RNAs that, upon binding to a protein mRNA chain, inhibit its synthesis, greatly affecting many processes in the body. ROS production and the effect of miRNA expression are linked to the development of many CVDs, so it is important to understand the relationship between these factors. Research into new suitable substances and methods that can positively affect the effects of excessive ROS formation on the cardiovascular system can significantly improve the quality of life of cardiological patients. The aim of the project is to look for suitable substances that will prevent toxic effects of excessively formed ROS and positively affect the mechanisms that cause damage. At the same time, elucidation of the role of miRNA involvement in signaling pathways associated with the action of ROS on the development and progression of various CVDs is also be presented.

NEISAD - The role of non-ischemic adaptive stimuli in protection of ischemic myocardium: study of triggering mechanisms and cardioprotective cell signaling

Úloha neischemických adaptačných stimulov v ochrane ischemického myokardu: štúdium spúšťacích mechanizmov a bunkovej kardioprotektívnej signalizácie.

Duration: 1. 7. 2019 - 30. 6. 2024
Program: APVV
Project leader: MUDr. Ravingerová Táňa DrSc., FIACS
Annotation:Cardiovascular diseases, especially ischemic heart disease (IHD) as a leading cause of heart failure and mortality worldwide, will not reduce over the coming decades despite the progress in pharmacotherapy, interventional cardiology and surgery. It is due to aging population and longer survival after acute myocardial infarction (MI), gradual decline of its function and incidence of comorbidities (diabetes, hypertension, dyslipidemia). Experimental studies revealed attenuation of MI by adaptive phenomenon of ischemic “conditioning“. However, it is not usually applicable in clinical medicine. In line with translation-oriented research, the project is aimed to: 1. verify the efficiency of cardioprotection induced by non-ischemic stimuli, such as motoric activity, hypoxia and non-invasive remote “conditioning“; 2. identify triggering mechanisms and pathways of signal transduction (“survival” cascades RISK and SAFE) to the target structures involved in heart injury reduction (mitochondrial permeability transition VV 2019 Základný výskum APVV-19-0540 Akronym: NEISAD 06.07.2020 10:48 Strana/Page: 2 pore, MPTP, nuclear PPAR receptors); 3. investigate the impact of comorbidities, age and gender on the adaptive processes considering functional, structural and subcellular cardiac alterations. Special emphasis will be placed on the role of small non-coding RNA (miRNA) regulating cell “survival” pathways and processes of apoptosis and necroptosis associated with cell oxidative state and Ca2+ homeostasis. We will focus on disclosure of the benefits of combination therapy: pleiotropic effects of PPAR agonists, MPTP inhibitors, coupled with noninvasive adaptive interventions not only under normal but also under pathological conditions (hypertension, hyperlipidemia, hyperglycemia). On animal in vivo and ex vivo models, combination of physiological, biochemical, selected biophysical and molecular biology methods will enable to elucidate processes of heart failing/regeneration and gain results that may lead to development of novel/modified strategies of IHD management.

Vazoactive effects of hydrogen sulphide signalling pathway and its interaction with nitric oxide in different animal models of metabolic syndrome

Vazoaktívne účinky sulfidovej signalizácie a jej interakcia s oxidom dusnatým v rôznych animálnych modeloch metabolického syndrómu

Duration: 1. 1. 2019 - 31. 12. 2022
Program: VEGA
Project leader: Mgr. Berényiová Andrea PhD.
Annotation:Nitric oxide (NO) and hydrogen sulphide (H2S) are signalling molecules involved into the regulation of the arterial tone. The synthesis of both has been shown in arterial wall, moreover their contribution in physiological (relaxation of arterial smooth muscle cells) and pathophysiological processes (hypertension, diabetes mellitus, atherosclerosis) have been already proved. Metabolic syndrome (MS) is a group of abnormalities including obesity, hypertension, hyperlipidemia which that together increase the risk of developing cardiovascular disease. Studies have characterised H2S signalisation and NO-H2S interaction especially in normotensive rats, information about their role in experimental hypertension are just limited and about their engagement into the etiopathogenesis of metabolic syndrome is totally missing. The main goal of this project is to describe the vasomotoric role of NO and H2S in different models of MS: induced by high-fructose diet, by high-fat diet in normotension and primary hypertension.

-

Vlastnosti erytrocytov a oxidačný stres za vybraných patológií a po podávaní antioxidantov

Duration: 1. 1. 2021 - 31. 12. 2024
Program: VEGA
Project leader: RNDr. Vrbjar Norbert CSc.

Effect of fructose diet in experimental models of metabolic syndrome and in healthy subjects: proposal of effective pharmacological treatment

Vplyv fruktózovej diéty v experimentálnych modeloch metabolického syndrómu a u zdravých jedincov: návrh účinnej farmakologickej liečby

Duration: 1. 1. 2019 - 31. 12. 2022
Program: VEGA
Project leader: RNDr. Gáspárová Zdenka PhD.
Annotation:The project will contribute to the knowledge about etiopathogenesis of metabolic syndrome (MetS). It extend the current project, where we study the impact of high-fat and high-fat-high-fructose diet on hypertriacylglycerolemic(HTG) rats. Chronic diseases such as MetS are generally multifactorial. Thus in their origin and development play a role not only environment (diet, physical activity, stress) but also genetic predisposition. In the new project, we will examine effect of fructose diet (FD) on various animal models (spontaneously hypertensive, HTG, Zucker obese/nonobese and Wistar healthy rats) and find which main risk factor of MetS together with FD cause the most serious damage. We will test the effect of the prospective pyridoindole SMe1EC2 and omega-3 fatty acids on the established model. By combining of these drugs, we expect increased effect on a number of risk factors of cardiovascular and cerebrovascular diseases without causing adverse effects, thus a proposal for a new more effective treatment.

The effect of aging and hypertension on experimental myocardial infarction

Vplyv starnutia a hypertenzie na experimentálny infarkt myokardu

Duration: 1. 1. 2020 - 31. 12. 2023
Program: VEGA
Project leader: RNDr. Cebová Martina PhD.
Annotation:Myocardial infarction is a serious cardiovascular disease associated with cardiac remodeling as a consequence of ischemia. Hypertension and aging aggravate the consequences of heart attack by the formation of oxidative and inflammatory mediators in the heart. Mereover, reperfusion after ischemia creates additional oxidative stress with a negative effect on myocardial tissue. To monitor the signaling molecules that can block or reverse the pathological process of infarction in hypertension is an important hypothesis for successful treatment of myocardial infarction. Therefore, our goal will be to exmine the effect of hypertension and aging on myocardial infarction and to analyze the effect of nitric oxide production, free oxygen radicals, and pleiotropic transcription factor Nrf2. In particular, the activation of Nrf2 and its target genes in elderly individuals may provide a novel mechanism of protection the myocardium from pathological cardiac remodeling.

Terapia KVO - Effect of therapy on redox regulation, biochemical markers and cell signaling of age-dependent cardiovascular and neurodegenerative diseases.

Vplyv terapie na redoxnú reguláciu, biochemické markery a bunkovú signalizáciu vekovo-závislých kardiovaskulárnych a neurodegeneratívnych ochorení.

Duration: 1. 1. 2020 - 31. 12. 2022
Program: VEGA
Project leader: doc. RNDr. Dovinová Ima PhD.
Annotation:In cardiovascular damage, oxidative stress is triggered by an increase in oxidative stress, affecting changes in the activities of SOD / NOS proteins, biochemical markers, metabolites, as well as redox regulation of SERCA Ca2 + -ATPases. Oxidative stress is a regulated antioxidant and detoxification response by activating the transcription factor Nrf2. The nuclear receptor and nutritional factor PPAR gamma is another regulator of signaling pathways that is positively linked to the regulation of Nrf2. PPAR gamma nuclear receptor agonists play an important role in the regulation of cardiovascular and hypertensive diseases.

The effect of virtual reality on the sensory regulation of balance control, physiological and psychological functions in humans

Vplyv virtuálnej reality na senzorickú reguláciu rovnováhy, fyziologické a psychologické funkcie človeka

Duration: 1. 1. 2019 - 31. 12. 2021
Program: VEGA
Project leader: Mgr. Hirjaková Zuzana PhD.
Annotation:Virtual reality (VR) is an environment that can be used to assess the postural and psycho-physiological parameters of different groups of people. The virtual environment provides an experience close to reality in laboratory conditions or at home. The aim of the project is to gain new knowledge about the body orientation, sensory regulation of balance control and the level of psycho-physiological stimulation in the VR. The volunteers will be introduced into the VR and at the same time their postural activity, reactions to vibratory stimulation of lower limb muscles, physiological and psychological level of arousal and stress will be recorded. We assume that the project results will provide the basis for designing promising methods for testing sensory balance control and psycho-physiological reactivity to the virtual environment. The obtained results may be helpful in rehabilitation of patients with postural balance disorders as well as people with psychological or physiological difficulties.

-

Výskum prírodných látok s terapeutickým potenciálom v humánnej medicíne: komplexná analýza, biologické účinky a štúdium synergie.

Duration: 1. 1. 2020 - 31. 12. 2023
Program: VEGA
Project leader: Ing. Račková Lucia PhD.
Annotation:Research work in the field of natural sources of antimicrobial active substances from the last two decades confirms the strong potential of natural substances and extracts, both in the eradication of resistant bacteria and fungi, but also in the prevention of biofilm formation and its destruction. The aim of this project is to test the biological activities of selected plant extracts, their secondary metabolites and their semisynthetic derivatives as potential antimicrobial and antibiofilm, as well as antioxidant, antiphlogistic and immunomodulatory agents. At the same time to exclude their cytotoxic potential on human cells in vitro and to evaluate the fingerprint of plant extracts by modern analytical methods. The target site for the action of these substances should be microbes colonizing skin infections (especially poorly healing, burns, surgical / postoperative wounds) and infections of the oral mucosa (especially the root canals of devital teeth and periradicular tissues). Another aim is to create a combination of active substances / extracts (synergistically acting), which will be adjusted to a gel base, which will be enriched with high-purity micronized beta-glucan in order to eradicate microbes on the skin and mucosa and promote tissue regeneration.

Projects total: 58